MOH — authorised 27 June 2012
- Marketing authorisation holder: EISAI INC
- Status: likely_approved
MOH authorised Belviq on 27 June 2012
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. MOH authorised it on 27 June 2012.
EISAI INC holds the Israeli marketing authorisation.